ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias

Trial Profile

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Givosiran (Primary)
  • Indications Acute intermittent porphyria; Porphyria
  • Focus Registrational; Therapeutic Use
  • Acronyms ENVISION
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 Status changed from planning to recruiting, according to an Alnylam Pharmaceuticals media release.
    • 07 Nov 2017 According to an Alnylam Pharmaceuticals media release, the company has reached an alignment with the EMA on the design of this trial.
    • 07 Sep 2017 According to an Alnylam Pharmaceuticals media release, the company expects interim analysis data in mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top